Chiung-Yu Huang.

Bronner P.D., Chiung-Yu Huang, Ph .D., Robert Morrison, M.Sc., Sarah Holte, Ph.D., Edward Kabyemela, M.D., Ph.D., D. Rebecca Prevots, Ph.D., Michal Fried, Ph.D., and Patrick E. Duffy, M.D.: Parasite Burden and Severity of Malaria in Tanzanian Children Although almost 600,000 African children die each year from malaria,1 most infections in children are mild.2,3 Fundamental questions about the pathogenesis of malaria remain unresolved, such as the relative contributions of parasite host and burden inflammation to severe disease.4 In areas where transmission is steady, severe malaria is unlikely to occur after 5 years, presumably because of immunity,5 and mathematical models claim that security against noncerebral severe malaria develops after one or two infections.6 The mechanism of protective immunity is unclear; it may, for example, involve the reduced amount of parasite density or the blocking of parasite virulence to avoid disease.

In all prespecified subgroups, the prices of grade 3 or higher pancreatic fistula, leak, or abscess were lower with pasireotide than with placebo. These reductions were significant in the subgroup of sufferers who underwent pancreaticoduodenectomy, those who underwent distal pancreatectomy, and those with a dilated pancreatic duct who underwent resection. The risk of overall pancreatic problems was also reduced with pasireotide. These total results claim that among patients who received pasireotide, not merely were many fistulas and leaks prevented, but when they did occur, they were less clinically relevant.